Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 4/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.41 |
| ▸ | BCL6 | P41182 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028168 | 0.92 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029628 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3025828 | 0.85 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3023684 | 0.83 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2524325 | 0.83 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3019502 | 0.83 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3026510 | 0.83 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3022713 | 0.83 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029902 | 0.82 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3029906 | 0.82 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | PSEN1, PSEN2, APP | PSEN1 1/4885PSEN2 2/4885APH1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.